Klin Onkol 2003; 16(3): 154-156.
Summary:
Backgrounds: Chemotherapy cisplatin etoposide (PE) with concomitant radiotherapy (RT) is a new standard treatment for limited disease small-cell lung cancer (LD SCLC). However, a 45 Gy dose of RT used in a key US Intergroup Trial 0096 is considered to be insufficient when administered conventionally, i.e. once daily 1.8 Gy, five days a week.
Design and subjects: Patients with LD SCLC, in very good performance status (WHO 0-I), were included into prospective nonrandomized study aimed on concomitant CT-RT with enhanced total dose of RT.
Methods and results: Four courses of PE and conventional radiotherapy 60 Gy were administered concurrently according to protocol. Seven patients were treated in the years 2000-2001. Overall response to therapy was 100%. Complete response: 1, partial response: 6 (in 5 of them the response was near to complete). Neutropenia occured in all patients, grade III IV (WHO) in 4 (57%). Other toxicities were grade I II only. Median survival time has not been reached yet.
Conclusions: Concurrent chemo-radiotherapy using 4 courses of PE and conventional RT is effective treatment of LD SCLC. Escalation of total conventional RT dose from 45 to 60 Gy is possible and suitable for clinical practice.
